Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | CFO | January 08, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TG THERAPEUTICS, INC.
Report date January 08, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 798,111 |
Reported balance
After 2026-01-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 90,000 · Balance 798,111 F1: Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30. F2: Includes shares of restricted Common Stock, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30.
F2: Includes shares of restricted Common Stock, which vest over various time periods.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Jan 9, 2026 22:15 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001015 · rdgdoc.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 798,111 F1 · shares: Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 22:15 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002290 · rdgdoc.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,111 F1 · shares: Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/26, 1/1/27, 1/1/28, and 1/1/29. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 23:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 10,021 | $28.53 | $285,939.21 |
DisclosureSEC source: 0001437749-25-000662 · rdgdoc.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,611 F1 · shares: In connection with the vesting of 45,000 shares on January 1, 2025, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 11,337 | $30.29 | $343,443.08 |
DisclosureSEC source: 0001437749-25-000662 · rdgdoc.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,632 F1 · shares: In connection with the vesting of 45,000 shares on January 1, 2025, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000756 · rdgdoc.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 681,969 F3 · shares: Reflects a grant of restricted shares, of which 1/4 will vest on 1/1/2025, 1/4 will vest on 1/1/2026, 1/4 will vest on 1/1/2027, and 1/4 will vest on 1/1/2028. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 47,867 | $16.91 | $809,430.97 |
DisclosureSEC source: 0001437749-24-000756 · rdgdoc.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,969 F1 · shares: In connection with the vesting of 95,000 shares on January 1, 2024, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| December 15, 2023 Filed Feb 15, 2024 02:53 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004259 · rdgdoc.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,969 F1 · security: Reflects the transfer of shares of TG Therapeutics stock to the Power Family and Descendants Trust. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 22:26 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 73,647 | $26.70 | $1,966,374.90 |
DisclosureSEC source: 0001104659-23-068182 · tm2317823-1_4seq1.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 654,836 F1 · shares: In connection with the vesting of 148,750 shares on May 31, 2023, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-032338 · tm239588-2_4seq1.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,483 F1 · shares: Reflects a grant of restricted shares, of which 1/4 will vest on 1/1/2024, 1/4 will vest on 1/1/2025, 1/4 will vest on 1/1/2026, and 1/4 will vest on 1/1/2027. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082024 · tm2221660-6_4seq1.xml · derivative · entry 2 Power Sean A · CIK 0001538845 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.001 · 200,000 shares Expires 2027-07-20 F3 · derivative.exercise_date: Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082024 · tm2221660-6_4seq1.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,483 F1 · shares: Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:11 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 9,653 | $18.31 | $176,746.43 |
DisclosureSEC source: 0001104659-22-002361 · tm222217d1_4.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,483 F1 · shares: In connection with the vesting of 160,000 shares on January 1, 2022, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting and 140,000 shares of TG Therapeutics stock issuable pursuant to stock options that are currently exercisable or exercisable within 60 days of this filing. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 23:11 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 75,312 | $19.20 | $1,445,990.40 |
DisclosureSEC source: 0001104659-22-002361 · tm222217d1_4.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,136 F1 · shares: In connection with the vesting of 160,000 shares on January 1, 2022, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:27 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084262 · tm2120405-7_4seq1.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,448 F1 · shares: Reflects a grant of restricted shares relating that will vest in according to the following schedule: 50% on January 1, 2022, and 25% on each of January 1, 2023 and 2024. F2 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting and 107,500 shares of TG Therapeutics stock issuable pursuant to stock options that are currently exercisable or exercisable within 60 days of this filing. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-000339 · tm211514d1_4.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,338 F1 · shares: Reflects a grant of restricted shares relating to 2020 service and performance. This award will vest in approximately equal tranches on January 1, 2022, 2023, 2024 and 2025. F2 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting. Read SEC document |
| December 21, 2020 Filed Feb 12, 2021 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-022085 · tm216578d1_5.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,438 F2 · security: Reflects the transfer of shares as a bona fide gift to a 501(c)(3) charitable organization. F3 · balance_after: Includes 107,500 shares of TG Therapeutics stock issuable pursuant to stock options that are currently exercisable or exercisable within 60 days of this filing. Read SEC document |
| October 09, 2020 Filed Feb 12, 2021 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-022085 · tm216578d1_5.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,438 F1 · security: Reflects the transfer of shares of TG Therapeutics stock to the Power Family and Descendants Trust. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-084949 · tm2025277d1_4.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,338 F3 · shares: Reflects a special long-term incentive award consisting of a grant of restricted shares that will vest in approximately equal tranches on January 1, 2021, 2022, 2023 and 2024. F2 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-084949 · tm2025277d1_4.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,338 F1 · shares: Reflects a grant of restricted shares relating to 2019 service and performance. This award will vest in approximately equal tranches on January 1, 2021, 2022, 2023 and 2024. F2 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 17,654 | $8.47 | $149,529.38 |
DisclosureSEC source: 0001654954-19-007935 · section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,338 F1 · kind: In connection with the vesting of 35,000 shares on June 30, 2019, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $8.41 to $9.26. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:21 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 37,275 | $4.13 | $153,945.75 |
DisclosureSEC source: 0001654954-19-000085 · section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,992 F1 · kind: In connection with the vesting of 72,500 shares on January 1, 2019, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average sales price. F3 · balance_after: Includes shares of restricted Common Stock, which are subject to vesting. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 00:21 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantEmployee Stock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001654954-19-000085 · section16.xml · derivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2028-12-31 F4 · derivative.exercise_date: The options vest according to the following schedule: 25% on each of January 1, 2020, January 1, 2021, January 1, 2022, and January 1, 2023. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 35,000 | $13.19 | $461,650.00 |
DisclosureSEC source: 0001654954-18-007370 · section16.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,267 F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 12,191 | $13.26 | $161,652.66 |
DisclosureSEC source: 0001654954-18-007370 · section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,267 F1 · kind: In connection with the vesting of 25,000 shares on June 30, 2018, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average sales price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 32,006 | $8.50 | $272,051.00 |
DisclosureSEC source: 0001654954-18-000068 · section16.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,458 F2 · kind: 32,006 shares were sold in connection with the vesting of 62,500 shares on January 1, 2018, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average sales price. F4 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-000068 · section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,464 F1 · shares: Reflects a grant of restricted shares that will vest according to the following schedule: 25% on January 1, 2019; 25% on January 1, 2020; and 50% on the later to occur of: (a) the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on December 31, 2017 and (b) January 1, 2019. Read SEC document |
| June 19, 2017 Filed Jun 19, 2017 22:05 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 30,000 | $11.04 | $331,200.00 |
DisclosureSEC source: 0001654954-17-005702 · section16.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,464 F2 · price: Represents the weighted average sales price. F3 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:05 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 29,976 | $11.14 | $333,932.64 |
DisclosureSEC source: 0001654954-17-005702 · section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,464 F1 · kind: In connection with the vesting of 58,334 shares on June 15, 2017, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average sales price. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 22:28 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 8,816 | $4.55 | $40,112.80 |
DisclosureSEC source: 0001354488-17-000035 · issuerdirect_section16.xml · nonDerivative · entry 2 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,440 F3 · kind: In connection with the vesting of 15,000 shares on January 1, 2017, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F4 · price: Represents the weighted average sales price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 22:28 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000035 · issuerdirect_section16.xml · nonDerivative · entry 1 Power Sean A · CIK 0001538845 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,256 F1 · shares: Reflects a grant of restricted shares that will vest according to the following schedule: 17.5% on January 1, 2018; 17.5% on January 1, 2019; 35% on the later to occur of: (a) the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on December 31, 2016 and (b) June 30, 2019; and 30% on performance based thresholds associated with the Company?s clinical programs. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.